{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,31]],"date-time":"2026-07-31T04:11:49Z","timestamp":1785471109199,"version":"3.56.0"},"reference-count":108,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,2,4]],"date-time":"2026-02-04T00:00:00Z","timestamp":1770163200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2026,3,6]],"date-time":"2026-03-06T00:00:00Z","timestamp":1772755200000},"content-version":"vor","delay-in-days":30,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"funder":[{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Discov Onc"],"DOI":"10.1007\/s12672-026-04542-y","type":"journal-article","created":{"date-parts":[[2026,2,4]],"date-time":"2026-02-04T21:46:38Z","timestamp":1770241598000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Cancer treatment-related cardiotoxicity, molecular mechanism, challenges, and research trends"],"prefix":"10.1007","volume":"17","author":[{"given":"Jia-yuan","family":"Ling","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lun-ming","family":"Wen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kangmin","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wei-qing","family":"Yuan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yi-ming","family":"Zhong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ping","family":"Lai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yong-ling","family":"Liao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,2,4]]},"reference":[{"issue":"11","key":"4542_CR1","doi-asserted-by":"publisher","first-page":"2475","DOI":"10.1158\/2159-8290.CD-22-1105","volume":"12","author":"KC Anderson","year":"2022","unstructured":"Anderson KC, Cantley LC, Dalla-Favera R, Dang CV, Diaz LA, DuBois RN, et al. The AACR journals: advancing progress toward the aacr\u2019s 115-Year mission. Cancer Discov. 2022;12(11):2475\u201381. https:\/\/doi.org\/10.1158\/2159-8290.CD-22-1105. PubMed PMID: 36321306.","journal-title":"Cancer Discov"},{"issue":"24","key":"4542_CR2","doi-asserted-by":"publisher","first-page":"1780","DOI":"10.1093\/jnci\/djn414","volume":"100","author":"D Mauri","year":"2008","unstructured":"Mauri D, Polyzos NP, Salanti G, Pavlidis N, Ioannidis JP. Multiple-treatments meta-analysis of chemotherapy and targeted therapies in advanced breast cancer. J Natl Cancer Inst. 2008;100(24):1780\u201391. https:\/\/doi.org\/10.1093\/jnci\/djn414. Epub 20081209. PubMed PMID: 19066278.","journal-title":"J Natl Cancer Inst"},{"issue":"41","key":"4542_CR3","doi-asserted-by":"publisher","first-page":"4229","DOI":"10.1093\/eurheartj\/ehac244","volume":"43","author":"AR Lyon","year":"2022","unstructured":"Lyon AR, Lopez-Fernandez T, Couch LS, Asteggiano R, Aznar MC, Bergler-Klein J, et al. 2022 ESC guidelines on cardio-oncology developed in collaboration with the European hematology association (EHA), the European society for therapeutic radiology and oncology (ESTRO) and the international Cardio-Oncology society (IC-OS). Eur Heart J. 2022;43(41):4229\u2013361. https:\/\/doi.org\/10.1093\/eurheartj\/ehac244. PubMed PMID: 36017568.","journal-title":"Eur Heart J"},{"issue":"18","key":"4542_CR4","doi-asserted-by":"publisher","first-page":"1720","DOI":"10.1093\/eurheartj\/ehaa006","volume":"41","author":"J Lopez-Sendon","year":"2020","unstructured":"Lopez-Sendon J, Alvarez-Ortega C, Zamora Aunon P, Buno Soto A, Lyon AR, Farmakis D, et al. Classification, prevalence, and outcomes of anticancer therapy-induced cardiotoxicity: the CARDIOTOX registry. Eur Heart J. 2020;41(18):1720\u20139. https:\/\/doi.org\/10.1093\/eurheartj\/ehaa006. PubMed PMID: 32016393.","journal-title":"Eur Heart J"},{"key":"4542_CR5","doi-asserted-by":"publisher","unstructured":"Zito C, Manganaro R, Ciappina G, Spagnolo CC, Racanelli V, Santarpia M, et al. Cardiotoxicity induced by immune checkpoint inhibitors: what a Cardio-Oncology team should know and do. Cancers (Basel). 2022. https:\/\/doi.org\/10.3390\/cancers14215403. Epub 20221102. PubMed PMID: 36358830; PubMed Central PMCID: PMC9653561.","DOI":"10.3390\/cancers14215403"},{"key":"4542_CR6","doi-asserted-by":"publisher","first-page":"117954681986644","DOI":"10.1177\/1179546819866445","volume":"13","author":"IE Perez","year":"2019","unstructured":"Perez IE, Taveras Alam S, Hernandez GA, Sancassani R. Cancer Therapy-Related cardiac dysfunction: an overview for the clinician. Clin Med Insights Cardiol. 2019;13:1179546819866445. 10.1177\/1179546819866445. Epub 20190729. PubMed PMID: 31384135; PubMed Central PMCID: PMC6664629.","journal-title":"Clin Med Insights Cardiol"},{"issue":"3","key":"4542_CR7","doi-asserted-by":"publisher","first-page":"e41","DOI":"10.1161\/CIR.0000000000000986","volume":"144","author":"MG Fradley","year":"2021","unstructured":"Fradley MG, Beckie TM, Brown SA, Cheng RK, Dent SF, Nohria A, et al. Recognition, Prevention, and management of arrhythmias and autonomic disorders in Cardio-Oncology: a scientific statement from the American heart association. Circulation. 2021;144(3):e41\u201355. https:\/\/doi.org\/10.1161\/CIR.0000000000000986. Epub 20210617. PubMed PMID: 34134525; PubMed Central PMCID: PMC8992663.","journal-title":"Circulation"},{"issue":"1","key":"4542_CR8","doi-asserted-by":"publisher","first-page":"31","DOI":"10.1038\/s41698-017-0034-x","volume":"1","author":"X Han","year":"2017","unstructured":"Han X, Zhou Y, Liu W. Precision cardio-oncology: understanding the cardiotoxicity of cancer therapy. NPJ Precis Oncol. 2017;1(1):31. https:\/\/doi.org\/10.1038\/s41698-017-0034-x. Epub 20170912.","journal-title":"NPJ Precis Oncol"},{"key":"4542_CR9","doi-asserted-by":"publisher","first-page":"4089","DOI":"10.2147\/DDDT.S469331","volume":"18","author":"F Gao","year":"2024","unstructured":"Gao F, Xu T, Zang F, Luo Y, Pan D. Cardiotoxicity of anticancer drugs: molecular Mechanisms, clinical management and innovative treatment. Drug Des Devel Ther. 2024;18:4089\u2013116. https:\/\/doi.org\/10.2147\/DDDT.S469331. Epub 20240912. PubMed PMID: 39286288; PubMed Central PMCID: PMC11404500.","journal-title":"Drug Des Devel Ther"},{"issue":"5","key":"4542_CR10","doi-asserted-by":"publisher","first-page":"1075","DOI":"10.1007\/s10741-025-10531-0","volume":"30","author":"S Shil","year":"2025","unstructured":"Shil S, Kumar P, Mumbrekar KD. Cancer therapy-induced cardiotoxicity: mechanisms and mitigations. Heart Fail Rev. 2025;30(5):1075\u201392. https:\/\/doi.org\/10.1007\/s10741-025-10531-0. Epub 20250607. PubMed PMID: 40481994; PubMed Central PMCID: PMC12297282.","journal-title":"Heart Fail Rev"},{"key":"4542_CR11","doi-asserted-by":"publisher","unstructured":"Slawinski G, Hawryszko M, Lizewska-Springer A, Nabialek-Trojanowska I, Lewicka E. Global longitudinal strain in Cardio-Oncology: a Review. Cancers (Basel). 2023. https:\/\/doi.org\/10.3390\/cancers15030986. Epub 20230203. PubMed PMID: 36765941; PubMed Central PMCID: PMC9913863.","DOI":"10.3390\/cancers15030986"},{"key":"4542_CR12","doi-asserted-by":"publisher","unstructured":"Adhikari A, Asdaq SMB, Al Hawaj MA, Chakraborty M, Thapa G, Bhuyan NR et al. Anticancer Drug-Induced Cardiotoxicity: Insights and Pharmacogenetics. Pharmaceuticals (Basel). 2021. https:\/\/doi.org\/10.3390\/ph14100970. Epub 20210925. PubMed PMID: 34681194; PubMed Central PMCID: PMC8539940.","DOI":"10.3390\/ph14100970"},{"issue":"4","key":"4542_CR13","doi-asserted-by":"publisher","first-page":"280","DOI":"10.1093\/eurheartj\/ehab674","volume":"43","author":"J Herrmann","year":"2022","unstructured":"Herrmann J, Lenihan D, Armenian S, Barac A, Blaes A, Cardinale D, et al. Defining cardiovascular toxicities of cancer therapies: an international Cardio-Oncology society (IC-OS) consensus statement. Eur Heart J. 2022;43(4):280\u201399. https:\/\/doi.org\/10.1093\/eurheartj\/ehab674. PubMed PMID: 34904661; PubMed Central PMCID: PMC8803367.","journal-title":"Eur Heart J"},{"issue":"5","key":"4542_CR14","doi-asserted-by":"publisher","first-page":"1741","DOI":"10.1002\/cam4.2813","volume":"9","author":"CM Oh","year":"2020","unstructured":"Oh CM, Lee D, Kong HJ, Lee S, Won YJ, Jung KW, et al. Causes of death among cancer patients in the era of cancer survivorship in korea: attention to the suicide and cardiovascular mortality. Cancer Med. 2020;9(5):1741\u201352. https:\/\/doi.org\/10.1002\/cam4.2813. Epub 20200120.","journal-title":"Cancer Med"},{"issue":"18","key":"4542_CR15","doi-asserted-by":"publisher","first-page":"1800","DOI":"10.1016\/j.jacc.2021.08.044","volume":"78","author":"A Goldman","year":"2021","unstructured":"Goldman A, Maor E, Bomze D, Liu JE, Herrmann J, Fein J, et al. Adverse cardiovascular and pulmonary events associated with chimeric antigen receptor T-Cell therapy. J Am Coll Cardiol. 2021;78(18):1800\u201313. https:\/\/doi.org\/10.1016\/j.jacc.2021.08.044. PubMed PMID: 34711339; PubMed Central PMCID: PMC8562317.","journal-title":"J Am Coll Cardiol"},{"key":"4542_CR16","doi-asserted-by":"publisher","unstructured":"Zamorano JL, Gottfridsson C, Asteggiano R, Atar D, Badimon L, Bax JJ et al. The cancer patient and cardiology. Eur J Heart Fail. 2020;22(12):2290\u2013309. https:\/\/doi.org\/10.1002\/ejhf.1985. Epub 20201002. PubMed PMID: 32809231; PubMed Central PMCID: PMC8278961.","DOI":"10.1002\/ejhf.1985"},{"key":"4542_CR17","doi-asserted-by":"publisher","first-page":"43","DOI":"10.1007\/164_2019_312","volume":"260","author":"M Khan","year":"2019","unstructured":"Khan M, Spicer J. The evolving landscape of cancer therapeutics. Handb Exp Pharmacol. 2019;260:43\u201379. https:\/\/doi.org\/10.1007\/164_2019_312. PubMed PMID: 31792681.","journal-title":"Handb Exp Pharmacol"},{"issue":"4","key":"4542_CR18","doi-asserted-by":"publisher","first-page":"451","DOI":"10.1097\/HCO.0000000000000637","volume":"34","author":"RS Copeland-Halperin","year":"2019","unstructured":"Copeland-Halperin RS, Liu JE, Yu AF. Cardiotoxicity of HER2-targeted therapies. Curr Opin Cardiol. 2019;34(4):451\u20138. 10.1097\/HCO.0000000000000637. PubMed PMID: 31082851; PubMed Central PMCID: PMC7313632.","journal-title":"Curr Opin Cardiol"},{"key":"4542_CR19","doi-asserted-by":"publisher","unstructured":"Tan S, Day D, Nicholls SJ, Segelov E. Immune Checkpoint Inhibitor Therapy in Oncology: Current Uses and Future Directions: JACC: CardioOncology State-of-the-Art Review. JACC CardioOncol. 2022;4(5):579\u201397. https:\/\/doi.org\/10.1016\/j.jaccao.2022.09.004. Epub 20221220. PubMed PMID: 36636451; PubMed Central PMCID: PMC9830229.","DOI":"10.1016\/j.jaccao.2022.09.004"},{"key":"4542_CR20","doi-asserted-by":"publisher","unstructured":"Brown SA, Ray JC, Herrmann J. Precision Cardio-Oncology: a Systems-Based Perspective on Cardiotoxicity of Tyrosine Kinase Inhibitors and Immune Checkpoint Inhibitors. Journal of cardiovascular translational research. 2020;13(3):402\u201316. Epub 20200406. https:\/\/doi.org\/10.1007\/s12265-020-09992-5. PubMed PMID: 32253744; PubMed Central PMCID: PMC8855704.","DOI":"10.1007\/s12265-020-09992-5"},{"key":"4542_CR21","doi-asserted-by":"publisher","unstructured":"Shelburne N, Adhikari B, Brell J, Davis M, Desvigne-Nickens P, Freedman A et al. Cancer treatment-related cardiotoxicity: current state of knowledge and future research priorities. J Natl Cancer Inst 2014. https:\/\/doi.org\/10.1093\/jnci\/dju232. Epub 20140910. PubMed PMID: 25210198; PubMed Central PMCID: PMC4176042.","DOI":"10.1093\/jnci\/dju232"},{"issue":"3","key":"4542_CR22","doi-asserted-by":"publisher","first-page":"515","DOI":"10.1016\/j.hfc.2022.01.001","volume":"18","author":"BB Adhikari","year":"2022","unstructured":"Adhikari BB, Shi S, Dimond EP, Shelburne N, Desvigne-Nickens P, Minasian LM. Spectrum of National institutes of Health-Funded research in Cardio-Oncology: a Basic, Clinical, and observational science perspective. Heart Fail Clin. 2022;18(3):515\u201328. PubMed PMID: 35718423; PubMed Central PMCID: PMC9328446.","journal-title":"Heart Fail Clin"},{"key":"4542_CR23","doi-asserted-by":"publisher","unstructured":"Fang K, Zhang Y, Liu W, He C. Effects of angiotensin-converting enzyme inhibitor\/angiotensin receptor blocker use on cancer therapy-related cardiac dysfunction: a meta-analysis of randomized controlled trials. Heart failure reviews. 2021;26(1):101-9. https:\/\/doi.org\/10.1007\/s10741-019-09906-x. PubMed PMID: 31900787.","DOI":"10.1007\/s10741-019-09906-x"},{"issue":"2","key":"4542_CR24","doi-asserted-by":"publisher","first-page":"e015327","DOI":"10.1161\/JAHA.119.015327","volume":"9","author":"SA Brown","year":"2020","unstructured":"Brown SA, Okwuosa TM, Barac A, Volgman AS. The role of Angiotensin-Converting enzyme inhibitors and beta-Blockers in primary prevention of cardiac dysfunction in breast cancer patients. J Am Heart Association. 2020;9(2):e015327. https:\/\/doi.org\/10.1161\/JAHA.119.015327. Epub 20200121.","journal-title":"J Am Heart Association"},{"issue":"27","key":"4542_CR25","doi-asserted-by":"publisher","first-page":"2562","DOI":"10.1093\/eurheartj\/ehab843","volume":"43","author":"C Lewinter","year":"2022","unstructured":"Lewinter C, Nielsen TH, Edfors LR, Linde C, Bland JM, LeWinter M, et al. A systematic review and meta-analysis of beta-blockers and renin-angiotensin system inhibitors for preventing left ventricular dysfunction due to anthracyclines or trastuzumab in patients with breast cancer. Eur Heart J. 2022;43(27):2562\u20139. https:\/\/doi.org\/10.1093\/eurheartj\/ehab843. PubMed PMID: 34951629.","journal-title":"Eur Heart J"},{"key":"4542_CR26","doi-asserted-by":"publisher","unstructured":"Avila MS, Ayub-Ferreira SM, de Barros Wanderley MR Jr., das, Dores Cruz F, Goncalves Brandao SM, Rigaud VOC et al. Carvedilol for Prevention of Chemotherapy-Related Cardiotoxicity: The CECCY Trial. J Am Coll Cardiol. 2018;71(20):2281-90. https:\/\/doi.org\/10.1016\/j.jacc.2018.02.049. Epub 20180311. PubMed PMID: 29540327.","DOI":"10.1016\/j.jacc.2018.02.049"},{"key":"4542_CR27","doi-asserted-by":"publisher","unstructured":"Kostakou PM, Kouris NT, Kostopoulos VS, Damaskos DS, Olympios CD. Cardio-oncology: a new and developing sector of research and therapy in the field of cardiology. Heart failure reviews. 2019;24(1):91\u2013100. https:\/\/doi.org\/10.1007\/s10741-018-9731-y. PubMed PMID: 30073443.","DOI":"10.1007\/s10741-018-9731-y"},{"issue":"Suppl 35","key":"4542_CR28","doi-asserted-by":"publisher","first-page":"S4282","DOI":"10.21037\/jtd.2018.08.15","volume":"10","author":"L Michel","year":"2018","unstructured":"Michel L, Rassaf T, Totzeck M. Biomarkers for the detection of apparent and subclinical cancer therapy-related cardiotoxicity. J Thorac Dis. 2018;10(Suppl 35):S4282\u201395. https:\/\/doi.org\/10.21037\/jtd.2018.08.15. PubMed PMID: 30701097; PubMed Central PMCID: PMC6328390.","journal-title":"J Thorac Dis"},{"key":"4542_CR29","doi-asserted-by":"publisher","unstructured":"Pivatto Junior F, Santos ABS, Englert EF, Mazzutti G, Costa GOM, Saffi MAL et al. Monocyte-to-lymphocyte ratio as predictor of cancer therapy-related cardiotoxicity in patients with breast cancer: a pilot cohort study. Breast cancer research and treatment. 2023;200(3):355\u201362. https:\/\/doi.org\/10.1007\/s10549-023-06979-zEpub 20230605. PubMed PMID: 37273150.","DOI":"10.1007\/s10549-023-06979-z"},{"issue":"4","key":"4542_CR30","doi-asserted-by":"publisher","first-page":"e15226","DOI":"10.1016\/j.heliyon.2023.e15226","volume":"9","author":"MT Cannizzaro","year":"2023","unstructured":"Cannizzaro MT, Inserra MC, Passaniti G, Celona A, D\u2019Angelo T, Romeo P, et al. Role of advanced cardiovascular imaging in chemotherapy-induced cardiotoxicity. Heliyon. 2023;9(4):e15226. https:\/\/doi.org\/10.1016\/j.heliyon.2023.e15226. Epub 20230405.","journal-title":"Heliyon"},{"key":"4542_CR31","doi-asserted-by":"publisher","first-page":"1139347","DOI":"10.3389\/fonc.2023.1139347","volume":"13","author":"PP Advani","year":"2023","unstructured":"Advani PP, Ruddy KJ, Herrmann J, Ray JC, Craver EC, Yothers G, et al. Replication of genetic associations of chemotherapy-related cardiotoxicity in the adjuvant NSABP B-31 clinical trial. Front Oncol. 2023;13:1139347. https:\/\/doi.org\/10.3389\/fonc.2023.1139347. Epub 20230525.","journal-title":"Front Oncol"},{"key":"4542_CR32","doi-asserted-by":"publisher","first-page":"102988","DOI":"10.1016\/j.critrevonc.2020.102988","volume":"153","author":"AKM Claessens","year":"2020","unstructured":"Claessens AKM, Ibragimova KIE, Geurts SME, Bos M, Erdkamp FLG, Tjan-Heijnen VCG. The role of chemotherapy in treatment of advanced breast cancer: an overview for clinical practice. Crit Rev Oncol Hematol. 2020;153:102988. https:\/\/doi.org\/10.1016\/j.critrevonc.2020.102988. Epub 20200526.","journal-title":"Crit Rev Oncol Hematol"},{"key":"4542_CR33","doi-asserted-by":"publisher","unstructured":"van der Zanden SY, Qiao X, Neefjes J. New insights into the activities and toxicities of the old anticancer drug doxorubicin. The FEBS journal. 2021;288(21):6095\u2013111. https:\/\/doi.org\/10.1111\/febs.15583. Epub 20201019. PubMed PMID: 33022843; PubMed Central PMCID: PMC8597086.","DOI":"10.1111\/febs.15583"},{"key":"4542_CR34","doi-asserted-by":"publisher","first-page":"101205","DOI":"10.1016\/j.mam.2023.101205","volume":"93","author":"R Mattioli","year":"2023","unstructured":"Mattioli R, Ilari A, Colotti B, Mosca L, Fazi F, Colotti G. Doxorubicin and other anthracyclines in cancers: activity, chemoresistance and its overcoming. Mol Aspects Med. 2023;93:101205. https:\/\/doi.org\/10.1016\/j.mam.2023.101205. Epub 20230727.","journal-title":"Mol Aspects Med"},{"key":"4542_CR35","doi-asserted-by":"publisher","first-page":"94","DOI":"10.1016\/j.ejca.2023.02.019","volume":"185","author":"WCM Dempke","year":"2023","unstructured":"Dempke WCM, Zielinski R, Winkler C, Silberman S, Reuther S, Priebe W. Anthracycline-induced cardiotoxicity\u2014are we about to clear this hurdle? Eur J Cancer. 2023;185:94\u2013104. https:\/\/doi.org\/10.1016\/j.ejca.2023.02.019. Epub 20230224.","journal-title":"Eur J Cancer"},{"key":"4542_CR36","doi-asserted-by":"publisher","unstructured":"Hung YC, Wang PW, Lin TY, Yang PM, You JS, Pan TL. Functional Redox Proteomics Reveal That Salvia miltiorrhiza Aqueous Extract Alleviates Adriamycin-Induced Cardiomyopathy via Inhibiting ROS-Dependent Apoptosis. Oxidative medicine and cellular longevity. 2020;2020:5136934. https:\/\/doi.org\/10.1155\/2020\/5136934. Epub 20200909. PubMed PMID: 32963697; PubMed Central PMCID: PMC7501560.","DOI":"10.1155\/2020\/5136934"},{"issue":"5","key":"4542_CR37","doi-asserted-by":"publisher","first-page":"162","DOI":"10.1007\/s13205-023-03584-1","volume":"13","author":"UP Mohan","year":"2023","unstructured":"Mohan UP, Pichiah PBT, Arunachalam S. Adriamycin downregulates the expression of KLF4 in cardiomyocytes in vitro and contributes to impaired cardiac energy metabolism in Adriamycin-induced cardiomyopathy. 3 Biotech. 2023;13(5):162. https:\/\/doi.org\/10.1007\/s13205-023-03584-1. Epub 20230504.","journal-title":"3 Biotech"},{"issue":"7","key":"4542_CR38","doi-asserted-by":"publisher","first-page":"3068","DOI":"10.1016\/S0021-9258(17)35747-2","volume":"261","author":"JH Doroshow","year":"1986","unstructured":"Doroshow JH, Davies KJ. Redox cycling of anthracyclines by cardiac mitochondria. II. Formation of superoxide anion, hydrogen peroxide, and hydroxyl radical. J Biol Chem. 1986;261(7):3068\u201374. PubMed PMID: 3005279.","journal-title":"J Biol Chem"},{"issue":"10","key":"4542_CR39","doi-asserted-by":"publisher","first-page":"R453","DOI":"10.1016\/j.cub.2014.03","volume":"24","author":"M Schieber","year":"2014","unstructured":"Schieber M, Chandel NS. ROS function in redox signaling and oxidative stress. Curr Biol. 2014;24(10):R453\u201362. https:\/\/doi.org\/10.1016\/j.cub.2014.03 .034. PubMed PMID: 24845678; PubMed Central PMCID: PMC4055301.","journal-title":"Curr Biol"},{"issue":"5","key":"4542_CR40","doi-asserted-by":"publisher","first-page":"376","DOI":"10.3969\/j.issn.1673-5374.2012.05","volume":"7","author":"X Chen","year":"2012","unstructured":"Chen X, Guo C, Kong J. Oxidative stress in neurodegenerative diseases. Neural Regen Res. 2012;7(5):376\u201385. https:\/\/doi.org\/10.3969\/j.issn.1673-5374.2012.05.009. PubMed PMID: 25774178; PubMed Central PMCID: PMC4350122.","journal-title":"Neural Regen Res"},{"issue":"1","key":"4542_CR41","doi-asserted-by":"publisher","first-page":"71","DOI":"10.1186\/s12915-021-00972-y","volume":"19","author":"DA Ammendolia","year":"2021","unstructured":"Ammendolia DA, Bement WM, Brumell JH. Plasma membrane integrity: implications for health and disease. BMC Biol. 2021;19(1):71. https:\/\/doi.org\/10.1186\/s12915-021-00972-y. Epub 20210413. PubMed PMID: 33849525; PubMed Central PMCID: PMC8042475.","journal-title":"BMC Biol"},{"issue":"1","key":"4542_CR42","doi-asserted-by":"publisher","first-page":"14","DOI":"10.1080\/10715762.2017.1402305","volume":"52","author":"MA Rosenfeld","year":"2018","unstructured":"Rosenfeld MA, Vasilyeva AD, Yurina LV, Bychkova AV. Oxidation of proteins: is it a programmed process? Free Radic Res. 2018;52(1):14\u201338. Epub 20171228. 10.1080\/10715762.2017.1402305. PubMed PMID: 29284315.","journal-title":"Free Radic Res"},{"issue":"7","key":"4542_CR43","doi-asserted-by":"publisher","first-page":"926","DOI":"10.1161\/CIRCRESAHA.119.314681","volume":"126","author":"KB Wallace","year":"2020","unstructured":"Wallace KB, Sardao VA, Oliveira PJ. Mitochondrial determinants of Doxorubicin-Induced cardiomyopathy. Circul Res. 2020;126(7):926\u201341. https:\/\/doi.org\/10.1161\/CIRCRESAHA.119.314681. Epub 20200326. PubMed PMID: 32213135; PubMed Central PMCID: PMC7121924.","journal-title":"Circul Res"},{"issue":"2","key":"4542_CR44","doi-asserted-by":"publisher","first-page":"617","DOI":"10.1172\/JCI72931","volume":"124","author":"Y Ichikawa","year":"2014","unstructured":"Ichikawa Y, Ghanefar M, Bayeva M, Wu R, Khechaduri A, Naga Prasad SV, et al. Cardiotoxicity of doxorubicin is mediated through mitochondrial iron accumulation. J Clin Investig. 2014;124(2):617\u201330. https:\/\/doi.org\/10.1172\/JCI72931. Epub 20140102. PubMed PMID: 24382354; PubMed Central PMCID: PMC3904631.","journal-title":"J Clin Investig"},{"key":"4542_CR45","doi-asserted-by":"publisher","first-page":"25","DOI":"10.3389\/fphar.2014.00025","volume":"5","author":"E Gammella","year":"2014","unstructured":"Gammella E, Maccarinelli F, Buratti P, Recalcati S, Cairo G. The role of iron in anthracycline cardiotoxicity. Front Pharmacol. 2014;5:25. https:\/\/doi.org\/10.3389\/fphar.2014.00025. Epub 20140226. PubMed PMID: 24616701; PubMed Central PMCID: PMC3935484.","journal-title":"Front Pharmacol"},{"issue":"19","key":"4542_CR46","doi-asserted-by":"publisher","first-page":"4278","DOI":"10.1002\/cncr.33102","volume":"126","author":"S Kunte","year":"2020","unstructured":"Kunte S, Abraham J, Montero AJ. Novel HER2-targeted therapies for HER2-positive metastatic breast cancer. Cancer. 2020;126(19):4278\u201388. https:\/\/doi.org\/10.1002\/cncr.33102. Epub 20200728. PubMed PMID: 32721042.","journal-title":"Cancer"},{"key":"4542_CR47","doi-asserted-by":"publisher","first-page":"852748","DOI":"10.1155\/2014\/852748","volume":"2014","author":"N Iqbal","year":"2014","unstructured":"Iqbal N, Iqbal N. Human epidermal growth factor receptor 2 (HER2) in cancers: overexpression and therapeutic implications. Mol Biol Int. 2014;2014:852748. https:\/\/doi.org\/10.1155\/2014\/852748. Epub 20140907. PubMed PMID: 25276427; PubMed Central PMCID: PMC4170925.","journal-title":"Mol Biol Int"},{"issue":"6555","key":"4542_CR48","doi-asserted-by":"publisher","first-page":"394","DOI":"10.1038\/378394a0","volume":"378","author":"KF Lee","year":"1995","unstructured":"Lee KF, Simon H, Chen H, Bates B, Hung MC, Hauser C. Requirement for neuregulin receptor erbB2 in neural and cardiac development. Nature. 1995;378(6555):394\u20138. https:\/\/doi.org\/10.1038\/378394a0. PubMed PMID: 7477377.","journal-title":"Nature"},{"issue":"5","key":"4542_CR49","doi-asserted-by":"publisher","first-page":"459","DOI":"10.1038\/nm0502-459","volume":"8","author":"SA Crone","year":"2002","unstructured":"Crone SA, Zhao YY, Fan L, Gu Y, Minamisawa S, Liu Y, et al. ErbB2 is essential in the prevention of dilated cardiomyopathy. Nat Med. 2002;8(5):459\u201365. https:\/\/doi.org\/10.1038\/nm0502-459. PubMed PMID: 11984589.","journal-title":"Nat Med"},{"key":"4542_CR50","doi-asserted-by":"publisher","unstructured":"Maadi H, Soheilifar MH, Choi WS, Moshtaghian A, Wang Z. Trastuzumab mechanism of Action; 20 years of research to unravel a dilemma. Cancers (Basel). 2021. https:\/\/doi.org\/10.3390\/cancers13143540. Epub 20210715. PubMed PMID: 34298754; PubMed Central PMCID: PMC8303665.","DOI":"10.3390\/cancers13143540"},{"key":"4542_CR51","doi-asserted-by":"publisher","unstructured":"Lee CC, Yang HL, Way TD, Kumar KJ, Juan YC, Cho HJ et al. Inhibition of Cell Growth and Induction of Apoptosis by Antrodia camphorata in HER-2\/neu-Overexpressing Breast Cancer Cells through the Induction of ROS, Depletion of HER-2\/neu, and Disruption of the PI3K\/Akt Signaling Pathway. Evid Based Complement Alternat Med. 2012;2012:702857. Epub 20120603. https:\/\/doi.org\/10.1155\/2012\/702857. PubMed PMID: 22701509; PubMed Central PMCID: PMC3371823.","DOI":"10.1155\/2012\/702857"},{"issue":"1","key":"4542_CR52","doi-asserted-by":"publisher","first-page":"5295","DOI":"10.1038\/s41598-018-23630-w","volume":"8","author":"C Schneider","year":"2018","unstructured":"Schneider C, Wallner M, Kolesnik E, Herbst V, Machler H, Pichler M, et al. The Anti-Cancer multikinase inhibitor Sorafenib impairs cardiac contractility by reducing phospholamban phosphorylation and sarcoplasmic calcium transients. Sci Rep. 2018;8(1):5295. https:\/\/doi.org\/10.1038\/s41598-018-23630-w. Epub 20180328.","journal-title":"Sci Rep"},{"key":"4542_CR53","doi-asserted-by":"publisher","unstructured":"Pottier C, Fresnais M, Gilon M, Jerusalem G, Longuespee R, Sounni NE. Tyrosine kinase inhibitors in cancer: breakthrough and challenges of targeted Therapy. Cancers (Basel). 2020.https:\/\/doi.org\/10.3390\/cancers12030731. Epub 20200320. PubMed PMID: 32244867; PubMed Central PMCID: PMC7140093.","DOI":"10.3390\/cancers12030731"},{"issue":"1","key":"4542_CR54","doi-asserted-by":"publisher","first-page":"262","DOI":"10.1038\/s41392-023-01469-6","volume":"8","author":"S Shyam Sunder","year":"2023","unstructured":"Shyam Sunder S, Sharma UC, Pokharel S. Adverse effects of tyrosine kinase inhibitors in cancer therapy: pathophysiology, mechanisms and clinical management. Signal Transduct Target Ther. 2023;8(1):262. https:\/\/doi.org\/10.1038\/s41392-023-01469-6. Epub 20230707.","journal-title":"Signal Transduct Target Ther"},{"issue":"3","key":"4542_CR55","doi-asserted-by":"publisher","first-page":"425","DOI":"10.1016\/j.hfc.2022.02.003","volume":"18","author":"SS Scott","year":"2022","unstructured":"Scott SS, Greenlee AN, Matzko A, Stein M, Naughton MT, Zaramo TZ, et al. Intracellular signaling pathways mediating tyrosine kinase inhibitor cardiotoxicity. Heart Fail Clin. 2022;18(3):425\u201342. https:\/\/doi.org\/10.1016\/j.hfc.2022.02.003. Epub 20220601.","journal-title":"Heart Fail Clin"},{"issue":"3","key":"4542_CR56","doi-asserted-by":"publisher","first-page":"197","DOI":"10.1038\/s41569-022-00770-1","volume":"20","author":"E Trimm","year":"2023","unstructured":"Trimm E, Red-Horse K. Vascular endothelial cell development and diversity. Nat Reviews Cardiol. 2023;20(3):197\u2013210. https:\/\/doi.org\/10.1038\/s41569-022-00770-1. Epub 20221005.","journal-title":"Nat Reviews Cardiol"},{"key":"4542_CR57","doi-asserted-by":"publisher","first-page":"204173142092059","DOI":"10.1177\/2041731420920597","volume":"11","author":"K Stamati","year":"2020","unstructured":"Stamati K, Redondo PA, Nyga A, Neves JB, Tran MG, Emberton M, et al. The anti-angiogenic tyrosine kinase inhibitor pazopanib kills cancer cells and disrupts endothelial networks in biomimetic three-dimensional renal tumouroids. J Tissue Eng. 2020;11:2041731420920597. https:\/\/doi.org\/10.1177\/2041731420920597. Epub 20200518. PubMed PMID: 32489578; PubMed Central PMCID: PMC7238304.","journal-title":"J Tissue Eng"},{"issue":"26","key":"4542_CR58","doi-asserted-by":"publisher","first-page":"5192","DOI":"10.1182\/blood-2013-03-490763","volume":"121","author":"J Ruan","year":"2013","unstructured":"Ruan J, Luo M, Wang C, Fan L, Yang SN, Cardenas M, et al. Imatinib disrupts lymphoma angiogenesis by targeting vascular pericytes. Blood. 2013;121(26):5192\u2013202. https:\/\/doi.org\/10.1182\/blood-2013-03-490763. Epub 20130430. PubMed PMID: 23632889; PubMed Central PMCID: PMC3695363.","journal-title":"Blood"},{"key":"4542_CR59","doi-asserted-by":"publisher","unstructured":"Gamrat A, Surdacki MA, Chyrchel B, Surdacki A. Endothelial dysfunction: a contributor to adverse cardiovascular remodeling and heart failure development in type 2 diabetes beyond accelerated atherogenesis. J Clin Med 2020. https:\/\/doi.org\/10.3390\/jcm9072090. Epub 20200703. PubMed PMID: 32635218; PubMed Central PMCID: PMC7408687.","DOI":"10.3390\/jcm9072090"},{"key":"4542_CR60","doi-asserted-by":"publisher","first-page":"113962","DOI":"10.1016\/j.biopha.2022.113962","volume":"157","author":"YT Chen","year":"2023","unstructured":"Chen YT, Masbuchin AN, Fang YH, Hsu LW, Wu SN, Yen CJ, et al. Pentraxin 3 regulates tyrosine kinase inhibitor-associated cardiomyocyte contraction and mitochondrial dysfunction via ERK\/JNK signalling pathways. Biomed pharmacotherapy = Biomedecine Pharmacotherapie. 2023;157:113962. https:\/\/doi.org\/10.1016\/j.biopha.2022.113962. Epub 20221110.","journal-title":"Biomed pharmacotherapy = Biomedecine Pharmacotherapie"},{"issue":"2","key":"4542_CR61","doi-asserted-by":"publisher","first-page":"H330","DOI":"10.1152\/ajpheart.00054.2019","volume":"317","author":"MJ Ivey","year":"2019","unstructured":"Ivey MJ, Kuwabara JT, Riggsbee KL, Tallquist MD. Platelet-derived growth factor receptor-alpha is essential for cardiac fibroblast survival. Am J Physiol Heart Circ Physiol. 2019;317(2):H330\u201344. https:\/\/doi.org\/10.1152\/ajpheart.00054.2019. Epub 20190524.","journal-title":"Am J Physiol Heart Circ Physiol"},{"issue":"1","key":"4542_CR62","doi-asserted-by":"publisher","first-page":"25","DOI":"10.1186\/s40959-023-00178-x","volume":"9","author":"I Ghafary","year":"2023","unstructured":"Ghafary I, Kim CK, Roth E, Lu M, Taub EM, Lee S, et al. The association of QTc prolongation with cardiovascular events in cancer patients taking tyrosine kinase inhibitors (TKIs). Cardiooncology. 2023;9(1):25. https:\/\/doi.org\/10.1186\/s40959-023-00178-x. Epub 20230519.","journal-title":"Cardiooncology"},{"key":"4542_CR63","doi-asserted-by":"publisher","first-page":"792310","DOI":"10.3389\/fcvm.2021.792310","volume":"8","author":"M Fazal","year":"2021","unstructured":"Fazal M, Kapoor R, Cheng P, Rogers AJ, Narayan SM, Wang P, et al. Arrhythmia patterns in patients on ibrutinib. Front Cardiovasc Med. 2021;8:792310. https:\/\/doi.org\/10.3389\/fcvm.2021.792310. Epub 20220103. PubMed PMID: 35047578; PubMed Central PMCID: PMC8761892.","journal-title":"Front Cardiovasc Med"},{"issue":"18","key":"4542_CR64","doi-asserted-by":"publisher","first-page":"3081","DOI":"10.1111\/bph.13942","volume":"174","author":"P Saxena","year":"2017","unstructured":"Saxena P, Hortigon-Vinagre MP, Beyl S, Baburin I, Andranovits S, Iqbal SM, et al. Correlation between human ether-a-go-go-related gene channel Inhibition and action potential prolongation. Br J Pharmacol. 2017;174(18):3081\u201393. https:\/\/doi.org\/10.1111\/bph.13942. Epub 20170811.","journal-title":"Br J Pharmacol"},{"key":"4542_CR65","doi-asserted-by":"publisher","first-page":"85","DOI":"10.1146\/annurev-pharmtox-022820-093805","volume":"61","author":"A Geraud","year":"2021","unstructured":"Geraud A, Gougis P, Vozy A, Anquetil C, Allenbach Y, Romano E, et al. Clinical Pharmacology and interplay of immune checkpoint agents: a Yin-Yang balance. Annu Rev Pharmacol Toxicol. 2021;61:85\u2013112. https:\/\/doi.org\/10.1146\/annurev-pharmtox-022820-093805. Epub 20200901.","journal-title":"Annu Rev Pharmacol Toxicol"},{"issue":"11","key":"4542_CR66","doi-asserted-by":"publisher","first-page":"1329","DOI":"10.1001\/jamacardio.2021.2241","volume":"6","author":"LH Lehmann","year":"2021","unstructured":"Lehmann LH, Cautela J, Palaskas N, Baik AH, Meijers WC, Allenbach Y, et al. Clinical strategy for the diagnosis and treatment of immune checkpoint Inhibitor-Associated myocarditis: a narrative review. JAMA Cardiol. 2021;6(11):1329\u201337. https:\/\/doi.org\/10.1001\/jamacardio.2021.2241. PubMed PMID: 34232253.","journal-title":"JAMA Cardiol"},{"key":"4542_CR67","doi-asserted-by":"publisher","unstructured":"Ma P, Liu J, Qin J, Lai L, Heo GS, Luehmann H et al. Expansion of disease specific cardiac macrophages in immune checkpoint inhibitor Myocarditis. bioRxiv. 2023. https:\/\/doi.org\/10.1101\/2023.04.28.538426. Epub 20230429. PubMed PMID: 37162929; PubMed Central PMCID: PMC10168426.","DOI":"10.1101\/2023.04.28.538426"},{"issue":"6","key":"4542_CR68","doi-asserted-by":"publisher","first-page":"111611","DOI":"10.1016\/j.celrep.2022.111611","volume":"41","author":"T Won","year":"2022","unstructured":"Won T, Kalinoski HM, Wood MK, Hughes DM, Jaime CM, Delgado P, et al. Cardiac myosin-specific autoimmune T cells contribute to immune-checkpoint-inhibitor-associated myocarditis. Cell Rep. 2022;41(6):111611. https:\/\/doi.org\/10.1016\/j.celrep.2022.111611. PubMed PMID: 36351411.","journal-title":"Cell Rep"},{"issue":"12","key":"4542_CR69","doi-asserted-by":"publisher","first-page":"1579","DOI":"10.1016\/S1470-2045(18)30608-9","volume":"19","author":"JE Salem","year":"2018","unstructured":"Salem JE, Manouchehri A, Moey M, Lebrun-Vignes B, Bastarache L, Pariente A, et al. Cardiovascular toxicities associated with immune checkpoint inhibitors: an observational, retrospective, pharmacovigilance study. Lancet Oncol. 2018;19(12):1579\u201389. https:\/\/doi.org\/10.1016\/S1470-2045(18)30608-9. Epub 20181112. PubMed PMID: 30442497; PubMed Central PMCID: PMC6287923.","journal-title":"Lancet Oncol"},{"issue":"3","key":"4542_CR70","doi-asserted-by":"publisher","first-page":"423","DOI":"10.2169\/internalmedicine.5317-20","volume":"60","author":"T Tsuruda","year":"2021","unstructured":"Tsuruda T, Yoshikawa N, Kai M, Yamaguchi M, Toida R, Kodama T, et al. The cytokine expression in patients with cardiac complication after immune checkpoint inhibitor therapy. Intern Med. 2021;60(3):423\u20139. https:\/\/doi.org\/10.2169\/internalmedicine.5317-20. Epub 20200919.","journal-title":"Intern Med"},{"key":"4542_CR71","doi-asserted-by":"publisher","unstructured":"Govindappa PK, Patil M, Garikipati VNS, Verma SK, Saheera S, Narasimhan G et al. Targeting exosome-associated human antigen R attenuates fibrosis and inflammation in diabetic heart. FASEB journal official publication of the federation of American societies for experimental biology. 2020;34(2):2238\u201351. https:\/\/doi.org\/10.1096\/fj.201901995R. Epub 20191216. PubMed PMID: 31907992; PubMed Central PMCID: PMC8286699.","DOI":"10.1096\/fj.201901995R"},{"issue":"3","key":"4542_CR72","doi-asserted-by":"publisher","first-page":"563","DOI":"10.1007\/s00441-016-2431-9","volume":"365","author":"V Talman","year":"2016","unstructured":"Talman V, Ruskoaho H. Cardiac fibrosis in myocardial infarction-from repair and remodeling to regeneration. Cell Tissue Res. 2016;365(3):563\u201381. https:\/\/doi.org\/10.1007\/s00441-016-2431-9. Epub 20160621.","journal-title":"Cell Tissue Res"},{"issue":"8","key":"4542_CR73","doi-asserted-by":"publisher","first-page":"1043","DOI":"10.1517\/14740338.2014.939953","volume":"13","author":"H Wang","year":"2014","unstructured":"Wang H, Guan F, Chen D, Dou QP, Yang H. An analysis of the safety profile of proteasome inhibitors for treating various cancers. Expert Opin Drug Saf. 2014;13(8):1043\u201354. https:\/\/doi.org\/10.1517\/14740338.2014.939953. Epub 20140709.","journal-title":"Expert Opin Drug Saf"},{"key":"4542_CR74","doi-asserted-by":"publisher","unstructured":"Uprety D, Mansfield AS. Targeting the Cardiotoxicity of Epidermal Growth Factor Receptor Inhibitors. JACC CardioOncol. 2020;2(1):11\u20132. https:\/\/doi.org\/10.1016\/j.jaccao.2020.02.005. Epub 20200317. PubMed PMID: 34396204; PubMed Central PMCID: PMC8352136.","DOI":"10.1016\/j.jaccao.2020.02.005"},{"key":"4542_CR75","doi-asserted-by":"publisher","unstructured":"Liang Z, He Y, Hu X, Cardio-Oncology. Mechanisms, drug Combinations, and reverse Cardio-Oncology. Int J Mol Sci. 2022. https:\/\/doi.org\/10.3390\/ijms231810617. Epub 20220913. PubMed PMID: 36142538; PubMed Central PMCID: PMC9501315.","DOI":"10.3390\/ijms231810617"},{"issue":"10","key":"4542_CR76","doi-asserted-by":"publisher","first-page":"3945","DOI":"10.1111\/cas.15068","volume":"112","author":"H Nakamura","year":"2021","unstructured":"Nakamura H, Takada K. Reactive oxygen species in cancer: current findings and future directions. Cancer Sci. 2021;112(10):3945\u201352. https:\/\/doi.org\/10.1111\/cas.15068. Epub 20210802. PubMed PMID: 34286881; PubMed Central PMCID: PMC8486193.","journal-title":"Cancer Sci"},{"key":"4542_CR77","doi-asserted-by":"publisher","unstructured":"Ganatra S, Chatur S, Nohria A. How to Diagnose and Manage Radiation Cardiotoxicity. JACC CardioOncol. 2020;2(4):655\u201360. https:\/\/doi.org\/10.1016\/j.jaccao.2020.07.010. Epub 20201117. PubMed PMID: 34396277; PubMed Central PMCID: PMC8352221.","DOI":"10.1016\/j.jaccao.2020.07.010"},{"key":"4542_CR78","doi-asserted-by":"publisher","first-page":"934369","DOI":"10.3389\/fonc.2022.934369","volume":"12","author":"A Abravan","year":"2022","unstructured":"Abravan A, Price G, Banfill K, Marchant T, Craddock M, Wood J, et al. Role of Real-World data in assessing cardiac toxicity after lung cancer radiotherapy. Front Oncol. 2022;12:934369. https:\/\/doi.org\/10.3389\/fonc.2022.934369. Epub 20220719.","journal-title":"Front Oncol"},{"issue":"18","key":"4542_CR79","doi-asserted-by":"publisher","first-page":"e021686","DOI":"10.1161\/JAHA.121.021686","volume":"10","author":"E Belzile-Dugas","year":"2021","unstructured":"Belzile-Dugas E, Eisenberg MJ. Radiation-Induced cardiovascular disease: review of an underrecognized pathology. J Am Heart Association. 2021;10(18):e021686. https:\/\/doi.org\/10.1161\/JAHA.121.021686Epub 20210906. PubMed PMID: 34482706; PubMed Central PMCID: PMC8649542.","journal-title":"J Am Heart Association"},{"key":"4542_CR80","doi-asserted-by":"publisher","unstructured":"Philipp J, Le Gleut R, Toerne CV, Subedi P, Azimzadeh O, Atkinson MJ et al. Radiation response of human cardiac endothelial cells reveals a central role of the cGAS-STING pathway in the development of Inflammation. Proteomes. 2020. Epub 20201026. https:\/\/doi.org\/10.3390\/proteomes8040030. PubMed PMID: 33114474; PubMed Central PMCID: PMC7709117.","DOI":"10.3390\/proteomes8040030"},{"key":"4542_CR81","doi-asserted-by":"publisher","unstructured":"Shi X, Young CD, Zhou H, Wang X. Transforming growth Factor-beta signaling in fibrotic diseases and Cancer-Associated fibroblasts. Biomolecules. 2020. https:\/\/doi.org\/10.3390\/biom10121666. Epub 20201212. PubMed PMID: 33322749; PubMed Central PMCID: PMC7763058.","DOI":"10.3390\/biom10121666"},{"key":"4542_CR82","doi-asserted-by":"publisher","unstructured":"Kim HJ, Kang SU, Lee YS, Jang JY, Kang H, Kim CH. Protective Effects of N-Acetylcysteine against Radiation-Induced Oral Mucositis In Vitro and In Vivo. Cancer Res Treat. 2020;52(4):1019-30. Epub 20200618. https:\/\/doi.org\/10.4143\/crt.2020.012. PubMed PMID: 32599978; PubMed Central PMCID: PMC7577823.","DOI":"10.4143\/crt.2020.012"},{"issue":"6","key":"4542_CR83","doi-asserted-by":"publisher","first-page":"973","DOI":"10.1093\/jrr\/rrt048","volume":"54","author":"VK Singh","year":"2013","unstructured":"Singh VK, Beattie LA, Seed TM, Vitamin E. Tocopherols and tocotrienols as potential radiation countermeasures. J Radiat Res. 2013;54(6):973\u201388. https:\/\/doi.org\/10.1093\/jrr\/rrt048. Epub 20130508.","journal-title":"J Radiat Res"},{"issue":"1","key":"4542_CR84","doi-asserted-by":"publisher","first-page":"96","DOI":"10.1016\/j.radonc.2014.11.017","volume":"114","author":"SJ van der Veen","year":"2015","unstructured":"van der Veen SJ, Ghobadi G, de Boer RA, Faber H, Cannon MV, Nagle PW, et al. ACE Inhibition attenuates radiation-induced cardiopulmonary damage. Radiother Oncol. 2015;114(1):96\u2013103. https:\/\/doi.org\/10.1016\/j.radonc.2014.11.017. Epub 20141125.","journal-title":"Radiother Oncol"},{"key":"4542_CR85","doi-asserted-by":"publisher","unstructured":"Group ESCSD. [2022 ESC Guidelines on cardio-oncology developed in collaboration with the European Hematology Association (EHA), the European Society for Therapeutic Radiology and Oncology (ESTRO) and the International Cardio-Oncology Society (IC-OS)]. G Ital Cardiol (Rome). 2023;24(2 Suppl 1):e1-e130. https:\/\/doi.org\/10.1714\/3967.39463. PubMed PMID: 36853174.","DOI":"10.1714\/3967.39463"},{"issue":"6","key":"4542_CR86","doi-asserted-by":"publisher","first-page":"730","DOI":"10.1016\/j.ccell.2021.04.013","volume":"39","author":"L Saulsberry","year":"2021","unstructured":"Saulsberry L, Olopade OI. Precision oncology: directing genomics and pharmacogenomics toward reducing cancer inequities. Cancer Cell. 2021;39(6):730\u20133. https:\/\/doi.org\/10.1016\/j.ccell.2021.04.013. Epub 20210520. PubMed PMID: 34019805; PubMed Central PMCID: PMC8323992.","journal-title":"Cancer Cell"},{"issue":"1","key":"4542_CR87","doi-asserted-by":"publisher","first-page":"8","DOI":"10.1186\/s13073-019-0703-1","volume":"12","author":"ER Malone","year":"2020","unstructured":"Malone ER, Oliva M, Sabatini PJB, Stockley TL, Siu LL. Molecular profiling for precision cancer therapies. Genome Med. 2020;12(1):8. https:\/\/doi.org\/10.1186\/s13073-019-0703-1. Epub 20200114.","journal-title":"Genome Med"},{"issue":"9","key":"4542_CR88","doi-asserted-by":"publisher","first-page":"1276","DOI":"10.1161\/CIRCRESAHA.117.310999","volume":"122","author":"K Trachana","year":"2018","unstructured":"Trachana K, Bargaje R, Glusman G, Price ND, Huang S, Hood LE. Taking systems medicine to heart. Circul Res. 2018;122(9):1276\u201389. https:\/\/doi.org\/10.1161\/CIRCRESAHA.117.310999. PubMed PMID: 29700072; PubMed Central PMCID: PMC5926821.","journal-title":"Circul Res"},{"issue":"2","key":"4542_CR89","doi-asserted-by":"publisher","first-page":"118","DOI":"10.1016\/j.tig.2023.10.012","volume":"40","author":"JA Morris","year":"2024","unstructured":"Morris JA, Sun JS, Sanjana NE. Next-generation forward genetic screens: uniting high-throughput perturbations with single-cell analysis. Trends Genet. 2024;40(2):118\u201333. https:\/\/doi.org\/10.1016\/j.tig.2023.10.012.","journal-title":"Trends Genet"},{"key":"4542_CR90","doi-asserted-by":"publisher","DOI":"10.1002\/mco2.660","author":"C Xu","year":"2024","unstructured":"Xu C, Jiang C, Li Z, Gao H, Xian J, Guo W, et al. Exosome nanovesicles: biomarkers and new strategies for treatment of human diseases. MedComm. 2024. https:\/\/doi.org\/10.1002\/mco2.660.","journal-title":"MedComm"},{"key":"4542_CR91","doi-asserted-by":"publisher","unstructured":"Park SW, Yeo NY, Kim T-H, Lim MN, Yim I, Kwon OB, et al. Explainable AI for colorectal cancer mortality and risk factor prediction in korea: a nationwide cancer cohort study. Int J Med Inf. 2026;205. https:\/\/doi.org\/10.1016\/j.ijmedinf.2025.106125.","DOI":"10.1016\/j.ijmedinf.2025.106125"},{"key":"4542_CR92","doi-asserted-by":"publisher","unstructured":"Peugnet V, Chwastyniak M, Mulder P, Lancel S, Bultot L, Fourny N et al. Mitochondrial-Targeted therapies require mitophagy to prevent oxidative stress induced by SOD2 inactivation in hypertrophied Cardiomyocytes. Antioxidants (Basel). 2022. Epub 20220406. https:\/\/doi.org\/10.3390\/antiox11040723. PubMed PMID: 35453408; PubMed Central PMCID: PMC9029275.","DOI":"10.3390\/antiox11040723"},{"key":"4542_CR93","doi-asserted-by":"publisher","first-page":"3741","DOI":"10.2147\/IJN.S250872","volume":"15","author":"R Pala","year":"2020","unstructured":"Pala R, Anju VT, Dyavaiah M, Busi S, Nauli SM. Nanoparticle-Mediated drug delivery for the treatment of cardiovascular diseases. Int J Nanomed. 2020;15:3741\u201369. https:\/\/doi.org\/10.2147\/IJN.S250872. Epub 20200527. PubMed PMID: 32547026; PubMed Central PMCID: PMC7266400.","journal-title":"Int J Nanomed"},{"key":"4542_CR94","doi-asserted-by":"publisher","unstructured":"Omidian H, Babanejad N, Cubeddu LX. Nanosystems in Cardiovascular Medicine: Advancements, Applications, and Future Perspectives. Pharmaceutics. 2023. https:\/\/doi.org\/10.3390\/pharmaceutics15071935. Epub 20230712. PubMed PMID: 37514121; PubMed Central PMCID: PMC10386572.","DOI":"10.3390\/pharmaceutics15071935"},{"key":"4542_CR95","doi-asserted-by":"publisher","unstructured":"Neacsu IA, Serban AP, Nicoara AI, Trusca R, Ene VL, Iordache F. Biomimetic composite scaffold based on naturally derived Biomaterials. Polymers (Basel). 2020. https:\/\/doi.org\/10.3390\/polym12051161. Epub 20200519. PubMed PMID: 32438578; PubMed Central PMCID: PMC7284724.","DOI":"10.3390\/polym12051161"},{"key":"4542_CR96","doi-asserted-by":"publisher","first-page":"2300","DOI":"10.1016\/j.csbj.2020.08.019","volume":"18","author":"Z Dlamini","year":"2020","unstructured":"Dlamini Z, Francies FZ, Hull R, Marima R. Artificial intelligence (AI) and big data in cancer and precision oncology. Comput Struct Biotechnol J. 2020;18:2300\u201311. https:\/\/doi.org\/10.1016\/j.csbj.2020.08.019. Epub 20200828.","journal-title":"Comput Struct Biotechnol J"},{"key":"4542_CR97","doi-asserted-by":"publisher","first-page":"1150933","DOI":"10.3389\/fmed.2023.1150933","volume":"10","author":"S Subramani","year":"2023","unstructured":"Subramani S, Varshney N, Anand MV, Soudagar MEM, Al-Keridis LA, Upadhyay TK, et al. Cardiovascular diseases prediction by machine learning incorporation with deep learning. Front Med. 2023;10:1150933. https:\/\/doi.org\/10.3389\/fmed.2023.1150933. Epub 20230417.","journal-title":"Front Med"},{"key":"4542_CR98","doi-asserted-by":"publisher","unstructured":"Shumba AT, Montanaro T, Sergi I, Bramanti A, Ciccarelli M, Rispoli A et al. Wearable technologies and AI at the Far edge for chronic heart failure prevention and management: A systematic review and Prospects. Sensors (Basel). 2023. https:\/\/doi.org\/10.3390\/s23156896. Epub 20230803. PubMed PMID: 37571678; PubMed Central PMCID: PMC10422393.","DOI":"10.3390\/s23156896"},{"key":"4542_CR99","doi-asserted-by":"publisher","unstructured":"Lopez-Fernandez T, Thavendiranathan P. Emerging cardiac imaging modalities for the early detection of cardiotoxicity due to anticancer Therapies. Revista Espanola de cardiologia (English ed). 2017;70(6):487\u201395. https:\/\/doi.org\/10.1016\/j.rec.2017.01.004. Epub 20170208. PubMed PMID: 28189542.","DOI":"10.1016\/j.rec.2017.01.004"},{"issue":"12","key":"4542_CR100","doi-asserted-by":"publisher","first-page":"1167","DOI":"10.1093\/ehjci\/jet065","volume":"14","author":"JA Urbano-Moral","year":"2013","unstructured":"Urbano-Moral JA, Arias-Godinez JA, Ahmad R, Malik R, Kiernan MS, DeNofrio D, et al. Evaluation of myocardial mechanics with three-dimensional speckle tracking echocardiography in heart transplant recipients: comparison with two-dimensional speckle tracking and relationship with clinical variables. Eur Heart J Cardiovasc Imaging. 2013;14(12):1167\u201373. https:\/\/doi.org\/10.1093\/ehjci\/jet065. Epub 20130423.","journal-title":"Eur Heart J Cardiovasc Imaging"},{"issue":"1","key":"4542_CR101","doi-asserted-by":"publisher","first-page":"101","DOI":"10.21037\/cdt.2017.06.01","volume":"8","author":"D Muraru","year":"2018","unstructured":"Muraru D, Niero A, Rodriguez-Zanella H, Cherata D, Badano L. Three-dimensional speckle-tracking echocardiography: benefits and limitations of integrating myocardial mechanics with three-dimensional imaging. Cardiovasc Diagn Ther. 2018;8(1):101\u201317. https:\/\/doi.org\/10.21037\/cdt.2017.06.01. PubMed PMID: 29541615; PubMed Central PMCID: PMC5835646.","journal-title":"Cardiovasc Diagn Ther"},{"key":"4542_CR102","doi-asserted-by":"publisher","unstructured":"Nikiforova A, Sedov I. Molecular design of magnetic resonance imaging agents binding to amyloid deposits. Int J Mol Sci. 2023. https:\/\/doi.org\/10.3390\/ijms241311152. Epub 20230706. PubMed PMID: 37446329; PubMed Central PMCID: PMC10342860.","DOI":"10.3390\/ijms241311152"},{"key":"4542_CR103","doi-asserted-by":"publisher","unstructured":"Kim PK, Hong YJ, Im DJ, Suh YJ, Park CH, Kim JY et al. Myocardial T1 and T2 Mapping: Techniques and Clinical Applications. Korean J Radiol. 2017;18(1):113\u201331. https:\/\/doi.org\/10.3348\/kjr.2017.18.1.113. Epub 20170105. PubMed PMID: 28096723; PubMed Central PMCID: PMC5240500.","DOI":"10.3348\/kjr.2017.18.1.113"},{"issue":"7","key":"4542_CR104","doi-asserted-by":"publisher","first-page":"465","DOI":"10.1038\/s41569-020-00503-2","volume":"18","author":"KC Siontis","year":"2021","unstructured":"Siontis KC, Noseworthy PA, Attia ZI, Friedman PA. Artificial intelligence-enhanced electrocardiography in cardiovascular disease management. Nat Reviews Cardiol. 2021;18(7):465\u201378. https:\/\/doi.org\/10.1038\/s41569-020-00503-2. Epub 20210201.","journal-title":"Nat Reviews Cardiol"},{"issue":"11","key":"4542_CR105","doi-asserted-by":"publisher","first-page":"1579","DOI":"10.1007\/s11912-022-01309-w","volume":"24","author":"J Muhandiramge","year":"2022","unstructured":"Muhandiramge J, Zalcberg JR, van Londen GJ, Warner ET, Carr PR, Haydon A, et al. Cardiovascular disease in adult cancer survivors: a review of current Evidence, strategies for prevention and Management, and future directions for Cardio-oncology. Curr Oncol Rep. 2022;24(11):1579\u201392. https:\/\/doi.org\/10.1007\/s11912-022-01309-w. Epub 20220707.","journal-title":"Curr Oncol Rep"},{"issue":"2","key":"4542_CR106","doi-asserted-by":"publisher","first-page":"89","DOI":"10.1007\/s40471-020-00235-4","volume":"7","author":"CC Cuthbertson","year":"2020","unstructured":"Cuthbertson CC, Pearce EE, Valle CG, Evenson KR. Cardiac rehabilitation programs for cancer survivors: a scoping review. Curr Epidemiol Rep. 2020;7(2):89\u2013103. https:\/\/doi.org\/10.1007\/s40471-020-00235-4. Epub 20200508.","journal-title":"Curr Epidemiol Rep"},{"issue":"1","key":"4542_CR107","doi-asserted-by":"publisher","first-page":"22","DOI":"10.1016\/j.jaccao.2022.12.007","volume":"5","author":"R Velusamy","year":"2023","unstructured":"Velusamy R, Nolan M, Murphy A, Thavendiranathan P, Marwick TH. Screening for coronary artery disease in cancer survivors: JACC: cardiooncology State-of-the-Art review. JACC CardioOncol. 2023;5(1):22\u201338. https:\/\/doi.org\/10.1016\/j.jaccao.2022.12.007. Epub 20230221.","journal-title":"JACC CardioOncol"},{"key":"4542_CR108","doi-asserted-by":"publisher","unstructured":"Leiva O, AbdelHameid D, Connors JM, Cannon CP, Bhatt DL. Common Pathophysiology in Cancer, Atrial Fibrillation, Atherosclerosis, and Thrombosis: JACC: CardioOncology State-of-the-Art Review. JACC CardioOncol. 2021;3(5):619\u201334. Epub 20211116. https:\/\/doi.org\/10.1016\/j.jaccao.2021.08.011. PubMed PMID: 34988471; PubMed Central PMCID: PMC8702799.","DOI":"10.1016\/j.jaccao.2021.08.011"}],"container-title":["Discover Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s12672-026-04542-y","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12672-026-04542-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12672-026-04542-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,3,6]],"date-time":"2026-03-06T10:45:01Z","timestamp":1772793901000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s12672-026-04542-y"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,2,4]]},"references-count":108,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["4542"],"URL":"https:\/\/doi.org\/10.1007\/s12672-026-04542-y","relation":{},"ISSN":["2730-6011"],"issn-type":[{"value":"2730-6011","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,2,4]]},"assertion":[{"value":"26 August 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"27 January 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"4 February 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"392"}}